Results 71 to 80 of about 5,445 (182)
Rare but relevant: MDMA and hyponatraemia
Addiction, Volume 121, Issue 3, Page 713-718, March 2026.Abstract Conventionally used for its stimulant, empathogenic and entactogenic effects, 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most commonly used psychoactive drugs, specifically among young adults and in nightlife and recreational party contexts.
Maria Rita Garcia +2 more
wiley +1 more source
V2 Receptor Antagonist: Tolvaptan
, 2011 Hyponatremia is the most common electrolyte disorder in hospitalized patients. Many studies documented that it was related to increased morbidity and mortality in patients with congestive heart failure, liver cirrhosis, and neurologic diseases.
���������
core +1 more source
Tolvaptan and its potential in the treatment of hyponatremia
, 2008 Megan B Dixon, Y Howard LienDepartment of Medicine, University of Arizona, Arizona Kidney Disease and Hypertension Center, Tucson, Arizona, USAAbstract: Tolvaptan is a selective arginine vasopressin (AVP) V2 receptor blocker used to induce free water ...
Y Howard Lien, Megan B Dixon
core
A Case of Paroxysmal Sympathetic Hyperactivity due to Cardiogenic Shock
Acute Medicine &Surgery, Volume 13, Issue 1, January/December 2026.Paroxysmal sympathetic hyperactivity (PSH) following cardiogenic shock without structural brain injury. A patient with cardiogenic shock requiring mechanical circulatory support developed recurrent episodes of hyperthermia, tachycardia, tachypnea, diaphoresis, and hypertonia during recovery.
Takahito Katsuyama +8 more
wiley +1 more source
, 2016 Tolvaptan is a selective V2-receptor antagonist primarily metabolized by CYP 3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug ...
Brouwer, Kenneth R. +7 more
core +1 more source
BMC Gastroenterology, 2020 Background To determine the safety and efficacy of different doses of tolvaptan for treating Chinese cirrhotic patients with or without hyponatraemia who still had ascites after routine therapy with diuretics.
Jieting Tang +19 more
doaj +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 220-229, January 2026.Aims This study investigated factors associated with and outcomes of combined loop diuretics with hydrochlorothiazide (HCTZ) for acute decompensated heart failure (ADHF). Methods In this retrospective study, adults hospitalized for ADHF and who received intravenous loop diuretics between January 2016 and March 2023 were enrolled.
Chia‐Chen Hsu +6 more
wiley +1 more source
Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients
, 2010 Savina Nodari1, Geoffrey T Jao2, Jun R Chiong31Division of Cardiology, University of Brescia, Brescia, Italy; 2Section of General Internal Medicine, Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA; 3Division of Cardiology, Loma ...
Savina Nodari +2 more
core
Long-term low-dose tolvaptan efficacy and safety in SIADH
, 2023 Purpose: Tolvaptan, a selective vasopressin V2-receptor antagonist, is approved for the treatment of SIADH-related hyponatremia, but its use is limited. The starting dose is usually 15 mg/day, but recent clinical experience suggests a lower starting dose
Irene Gagliardi +9 more
core +1 more source
Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
Case Reports in Nephrology and Dialysis, 2018 A 59-year-old Japanese woman was admitted for evaluation of muscle weakness. Autosomal dominant polycystic kidney disease had been diagnosed at the age of 47 years, followed by primary aldosteronism at 53 years.
Kyohei Kunizawa +14 more
doaj +1 more source